Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes

Bibliography

• Thom T, Haase N, Rosamond W, Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113(6):e85-151
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4-8
   PubMed Web of Science ®Google Scholar
• Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21(1):23-9
   PubMed Web of Science ®Google Scholar
• Mann KG, Butenas S, Brummel K, The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23(1):17-25
   PubMedGoogle Scholar
• Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451(7181):914-18
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373(9676):1673-80
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19
   PubMed Web of Science ®Google Scholar
• Xu XS, Moore K, Burton P, Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 2012, doi: 10.1111/j.1365-2125.2012.04181.x.
   Google Scholar
• Ruff CT, Giugliano RP, Antman EM, Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160(4):635-41
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM, Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159(3):331-9
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3(3):514-21
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J, Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005;48(19):5900-8
   PubMed Web of Science ®Google Scholar
• Mann KG. Thrombin formation. Chest 2003;124(3 Suppl):4S-10S
   PubMedGoogle Scholar
• Mann KG, Brummel K, Butenas S, What is all that thrombin for? J Thromb Haemost 2003;1(7):1504-14
   PubMed Web of Science ®Google Scholar
• Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15(8):843-55
   PubMed Web of Science ®Google Scholar
• Tersteegen A, Schmidt S, Burkhardt N. Rivaroxaban – an oral, direct factor Xa inhibitor – binds rapidly to factor Xa. J Thromb Haemost 2007;5(Suppl 2):abstract P-W-651
   Google Scholar
• Varin R, Mirshahi S, Mirshahi P, Effect of rivaroxaban, an oral direct factor Xa inhibitor, on whole blood clot permeation and thrombolysis: critical role of red blood cells. Blood (ASH Annual Meeting Abstracts) 2009;114:1064
   Google Scholar
• Depasse F, Busson J, Mnich J, Effect of BAY 59-7939 – a novel, oral, direct factor Xa inhibitor – on clot-bound factor Xa activity in vitro. J Thromb Haemost 2005;3(Suppl 1):P1104
   Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007;5(4):886-8
   PubMed Web of Science ®Google Scholar
• Koda-Kimble MA, Young LY, Alldredge BK, editors. Applied Therapeutics: The Clinical Use of Drugs. 9th edition. Lippincott Williams & Wilkins, Baltimore, MD; 2009
   Google Scholar
• Zhou Q, Bea F, Preusch M, Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011;2011:432080
   PubMed Web of Science ®Google Scholar
• Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501
   Google Scholar
• Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951;3:201-8
   PubMed Web of Science ®Google Scholar
• Mueck W, Lensing AW, Agnelli G, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50(10):675-86
   PubMed Web of Science ®Google Scholar
• Mueck W, Borris LC, Dahl OE, Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100(3):453-61
   PubMed Web of Science ®Google Scholar
• Mueck W, Eriksson BI, Bauer KA, Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47(3):203-16
   PubMed Web of Science ®Google Scholar
• Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012;26(1):27-32
   PubMedGoogle Scholar
• Kubitza D, Becka M, Voith B, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21
   PubMed Web of Science ®Google Scholar
• Bayer Schering Pharma AG. Xarelto® summary of product characteristics. Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100 2011. [Last accessed 23 December 2011]
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
   PubMed Web of Science ®Google Scholar
• CHMP assessment report for Xarelto. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf
   Google Scholar
• Kubitza D, Becka M, Roth A, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, cross-over study in healthy subjects. Circulation 2011;124(14):1573-9
   PubMed Web of Science ®Google Scholar
• Mueck W, Becka M, Kubitza D, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor xa inhibitor – in healthy subjects. Int J Clin Pharmacol Ther 2007;45(6):335-44
   PubMedGoogle Scholar
• Agnelli G, Gallus A, Goldhaber SZ, Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007;116(2):180-7
   PubMedGoogle Scholar
• Turpie AG, Fisher WD, Bauer KA, BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3(11):2479-86
   PubMed Web of Science ®Google Scholar
• Mueck W, Lensing AW, Agnelli G, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50(10):675-86
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE, Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4(1):121-8
   PubMedGoogle Scholar
• Clark B. Biology of renal aging in humans. Adv Ren Replace Ther 2000;7(1):11-21
   PubMedGoogle Scholar
• Mueck W, Becka M, Kubitza D, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects. Int J Clin Pharmacol Ther 2007;45:335-44
   PubMed Web of Science ®Google Scholar
• Mueck W, Eriksson BI, Bauer KA, Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47:203-16
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48(1):1-22
   PubMed Web of Science ®Google Scholar
• Weinz C, Schwarz T, Kubitza D, Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009;37(5):1056-64
   PubMed Web of Science ®Google Scholar
• Gulseth MP, Michaud J, Nutescu EA, Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 2008;65(16):1520-9
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70(5):703-12
   PubMed Web of Science ®Google Scholar
• Weinz C, Schwartz T, Pleiss U, Metabolism and distribution of [14C] BAY 59–7939 – an oral, direct factor Xa inhibitor – in rat, dog and human. Drug Metab Rev 2004;36:A 196
   Google Scholar
• Gnoth MJ, Buetehorn U, Muenster U, In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338(1):372-80
   PubMed Web of Science ®Google Scholar
• Moore KT, Plotnikov AN, Thyssen A, Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011;58(6):581-8
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, Rivaroxaban (BAY 59-7939) – an oral, direct factor Xa inhibitor – has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007;63(4):469-76
   PubMedGoogle Scholar
• Kubitza D, Becka M, Mueck W, Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin. J Clin Pharmacol 2006;46:981-90
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. [abstract 11]. J Clin Pharmacol 2006;46:702
   Google Scholar
• Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban – a novel, oral, direct factor Xa inhibitor – and atorvastatin. Pathophysiol Haemost Thromb 2008;36:A40
   Google Scholar
• Weinz C, Radtke M, Schmeer K, In vitro metabolism of BAY 59-7939 – an oral, direct factor Xa inhibitor. Drug Metab Rev 2004;36(Suppl 1):195
   Google Scholar
• Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, Pharmacology of the oral, direct Factor Xa inhibitor rivaroxaban – effect of extreme age and gender. Hamostaseologie 2007;27:A40
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47:218-26
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, The effect of age, gender and weight on the safety and pharmacology of rivaroxaban (BAY 59-7939) – a novel, oral, direct Factor Xa inhibitor. Clinical Pharmacology, and Department of Biometry, Pharmacometry, Bayer HealthCare AG, Wuppertal, Germany
   Google Scholar
• Halabi A, Kubitza D, Zuehlsdorf M, Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban an oral, direct factor Xa inhibitor. J Thromb Haemost 2007;5(Suppl 2):P-M-635
   Google Scholar
• Berry CN, Girard D, Girardot C, Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996;22:233
   PubMed Web of Science ®Google Scholar
• Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994;113:1209-14
   PubMed Web of Science ®Google Scholar
• Sato K, Taniuchi Y, Kawasaki T, Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998;347:231-6
   PubMed Web of Science ®Google Scholar
• Becker EM, Perzborn E, Klipp A, Effects of rivaroxaban, ASA and clopidogrel alone and in combination in a porcine model of stent thrombosis. Available from: http://spo.escardio.org/eSlides/view.aspx?eevtid=40&fp=5063 and http://www.xarelto.com/html/images/events/ESC/Abstract-Becker.pdf [Last accessed 20 February 2012]
   Google Scholar
• Tricoci P, Huang Z, Held C, Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
   PubMed Web of Science ®Google Scholar
• Merlini PA, Bauer KA, Oltrona L, Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90(1):61-8
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, for the TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, for the PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Celestin C, Fiore LD, Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50
   PubMed Web of Science ®Google Scholar
• APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85
   PubMed Web of Science ®Google Scholar
• Apixaban: Summary of product characteristics. Available from: http://ec.europa.eu/health/documents/community-register/2011/20110518102349/anx_102349_en.pdf [Last accessed 20 February 2012]
   Google Scholar
• Raghavan N, Frost CE, Yu Z, Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37(1):74-81
   PubMed Web of Science ®Google Scholar